Addendum

Nivolumab (urothelial carcinoma, adjuvant) - Addendum to Commission A22-53

Status
Status: Commission completed
Project no.
A22-97
Last updated

Report documents

  1. Addendum

    Nivolumab (urothelial carcinoma, adjuvant) - Addendum to Commission A22-53

    published on
    Document type
    PDF document, 894 kB, EN, not accessible

Dossier assessment

Indication:

Adult patients with muscle invasive urothelial carcinoma with tumour cell PD-L1 expression ≥ 1%, who are at high risk of recurrence after complete resection

Result of dossier assessment:

Unchanged after addendum:

  • Patients who are eligible for cisplatin-containing therapy for adjuvant treatment: added benefit not proven
  • Patients who are not eligible for cisplatin-containing therapy for adjuvant treatment: hint of minor added benefit

Additional information

Federal Joint Committee (G-BA)

2022-10-20 A G-BA decision was published.

G-BA documents on this decision

Project details

Project no.
A22-97
Commission
Commission awarded on 06.09.2022 by the Federal Joint Committee (GBA).
Report type
Addendum
Status
Commission completed
Department/Division
Drug Assessment
Topic
Cancer
Note

If the need for additional work on a project commissioned by the GBA arises during consultations, IQWiG submits an addendum. The subsequent decides on the extent of the added benefit concludes the early benefit assessment.

Connected Projects

  1. Dossier assessment

    Nivolumab (urothelial carcinoma, adjuvant) - Benefit assessment according to §35a Social Code Book V

    Project no.
    A22-53
    Last updated

    Status: Commission completed

Contact

Info Service (German)

Subscribe to daily updated information on projects, calls for tender, current vacancies and events as well as our press releases.

Register

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.

Contact form